Viome sells an at-home stool kit and returns a ranking of thousands of foods, sorted into Superfood, Enjoy, Minimize and Avoid. Its methodological differentiator is real: rather than sequencing DNA to census which organisms are present, it sequences RNA to measure which organisms are transcribing genes. That distinction is the main reason the product costs what it does, and it is also the source of its least-discussed weakness.
The question for a buyer is narrower than "does the science work." The sequencing works. What a buyer is really deciding is whether a proprietary model turning that sequencing into a food list will change what they eat, and whether they will retest often enough for the number to mean anything. This review covers cost by tier, the accuracy limits, the collection experience, what the output can and cannot support, and where a different purchase makes more sense.
The Verdict
Scorecard
| Category | Score | Why |
|---|---|---|
| Methodology | 8/10 | Metatranscriptomic RNA sequencing measures which organisms are transcribing genes, not only which are present |
| Method disclosure | 8/10 | The sequencing approach is stated openly; the scoring model built on top of it is not published |
| Recommendation depth | 9/10 | Food scores across thousands of items, plus supplement and probiotic formulations |
| Sample collection | 7/10 | At-home stool kit with a preservative tube, mailed back; no clinic visit |
| Turnaround | 6/10 | Roughly 2–4 weeks from posting the sample to results in the app |
| Actionability | 6/10 | Scores are specific, but some contradict standard nutrition advice with no visible reasoning |
| Independent validation | 5/10 | Most published work supporting the scoring model comes from the company itself |
| Value at price | 6/10 | $149–$399 per test as of 2026, plus an optional supplement subscription |
Cost and what each tier includes
Pricing moves with promotions and subscription terms, so treat these as ranges to confirm rather than fixed figures. The structure is stable even when the numbers are not: a gut-only entry tier, wider bundles above it, and a separate supplement subscription.
| Tier | Typical 2026 price | What is included | Who it is aimed at |
|---|---|---|---|
| Gut Intelligence | Roughly $149–$229 | Stool sample, gut microbial activity scores, personalized food scores | Someone testing the category once |
| Health Intelligence | Roughly $249–$329 | Adds a blood component and cellular or biological-age style scores | Someone who wants blood markers bundled in |
| Full Body Intelligence | Roughly $349–$399 | Adds oral microbiome sampling and the widest score set | Someone committed to annual retesting |
| Precision Supplements | Roughly $60–$200 per month | Custom-blended supplements and probiotics generated from your results | Optional; sold separately from the test |
The budgeting mistake is anchoring on the single test price. Viome positions annual retesting as part of the model, and its own recommendation engine routes toward a supplement subscription. A realistic three-year commitment at the middle tier with supplements lands well above $2,000, which is a different purchase than a one-off $199 kit. Decide up front which of the two you are making.
How the methodology works, and where it loses accuracy
Metatranscriptomics reads RNA rather than DNA. Because RNA is produced when a gene is being expressed, the resulting profile describes activity rather than presence, and it captures organisms across kingdoms — bacteria, archaea, fungi, and viruses — rather than bacteria alone.
Three limits sit underneath that. The first is fragility: RNA starts degrading within hours of collection, so the preservative in the tube and the time your sample spends in transit both shape the result. A kit that sat in a warm mailbox over a weekend can return a materially different profile than the same sample handled promptly, and nothing in the report distinguishes the two. The second is database coverage — interpreting expression requires reference data that is thinner than the equivalent DNA references. The third is the one that matters most for a consumer: the step from sequencing output to a food score is a proprietary model, and no amount of sequencing quality validates that step.
Collection experience and turnaround
The process is straightforward and takes about ten minutes of actual effort. A kit arrives with a collection paper, a swab, and a tube containing preservative. You collect a small stool sample, seal it, register the kit barcode in the app, and post it back in the supplied packaging. Higher tiers add a finger-prick blood collection card and, at the top tier, an oral swab, each with their own tube.
Turnaround runs roughly two to four weeks from posting to results appearing in the app, with the blood-based components sometimes landing separately from the gut results. Two details are worth planning around. Post the sample early in the week rather than on a Friday, so it is not sitting in a distribution centre over a weekend — this matters more for RNA than it would for a DNA-based product. And do not collect during or shortly after a course of antibiotics, an episode of gastroenteritis, or international travel.
What the output actually tells you
The report is dense, which is part of the appeal and part of the problem. Each element carries a different weight of evidence, and the interface presents them with equal confidence.
| Output | What it shows you | What it is actually based on | What it cannot tell you |
|---|---|---|---|
| Food scores | Every food ranked Superfood, Enjoy, Minimize or Avoid for you | A ranking produced by a proprietary model from your sample | Whether following the ranking improves a clinical outcome |
| Microbial activity scores | Composite scores for gut lining, digestive efficiency, inflammatory activity, gas production | A summary of transcriptional signals mapped onto named categories | A diagnosis, or a comparison against a validated clinical reference range |
| Organism list | Species detected and their relative activity | Which organisms were transcribing at the moment of collection | Whether that snapshot repeats next month |
| Supplement recommendations | A custom formula built from your scores | Ingredients selected by the same company that sells them | Independent confirmation that the formula addresses what the report found |
| Biological age (higher tiers) | A single age-style number | An estimate from a separate assay | Comparability with any other vendor’s biological age result |
The most common source of user frustration is a food with strong general evidence scoring poorly — blueberries, spinach, tomatoes. Two explanations fit equally well. It may be capturing a real feature of your microbial activity, which is the entire premise of the product. Or it may be an artifact of a model with limited validation. The report gives you no way to distinguish them, and no traceable reasoning from a specific finding to a specific food. That opacity is the single biggest limit on acting confidently on the output.
Who it fits, and who should buy something else
| Your situation | Verdict | Reasoning |
|---|---|---|
| You want a structured food framework and will actually use it | Good fit | The output is a concrete list, which some people follow far better than general advice |
| You plan to retest annually and track change | Good fit | The product is designed around repeat measurement, and single readings are the weakest use |
| You are curious about your microbiome and can absorb the cost | Reasonable fit | Treat the sequencing as real and the scorecard as a model |
| You have GI symptoms you want explained | Poor fit | Bloating, diarrhea, and pain need a clinical workup — start with the symptom-matched test |
| You suspect small intestinal overgrowth | Poor fit | A stool sample cannot see the small intestine; a breath test is the relevant instrument |
| You want colorectal cancer screening | Poor fit | No consumer microbiome test screens for colorectal cancer; FIT or colonoscopy does |
| You have never run a standard blood panel | Poor fit | A basic panel costs less and names specific, treatable problems |
| You are within 3 months of an antibiotic course | Wait | The sample will report the antibiotic rather than your ordinary state |
Trade-offs to weigh before buying
- Specificity versus traceability. The food list is far more concrete than general dietary advice, and far less explainable. You cannot see which finding produced which recommendation, so you cannot sanity-check an odd result.
- RNA richness versus RNA fragility. The method that gives Viome its differentiator is also the method most exposed to shipping conditions.
- Vertical integration. Custom supplements make acting on the results easy, and mean the interpreter of your data also sells the remedy. The arrangement is disclosed; weigh it as you would any vendor recommendation for its own product.
- Recurring cost. Value depends on repeat measurement, so the real cost horizon is years rather than one kit.
- No diagnostic role. The product does not detect pathology, and a clean-looking report should never delay a workup for a red-flag symptom.
How it compares to the direct alternatives
Listed alphabetically, with the clinical route last because it is not a consumer product.
| Option | Method | Typical cost | Primary output | Fits someone who |
|---|---|---|---|---|
| Viome | Metatranscriptomic RNA sequencing of stool | Roughly $149–$399 per test | Food scores plus own-brand supplements | Wants a granular food ranking from microbial activity |
| Zoe | Metagenomic DNA sequencing plus a 14-day CGM and a blood-fat challenge | Roughly $300–$500 up front plus an ongoing membership | Food scores driven mainly by measured metabolic response | Wants personalization anchored to measured glucose and blood-fat responses |
| Clinical stool testing via a physician | Targeted assays: calprotectin, PCR pathogen panel, elastase | $50–$400 per test, frequently insurance-covered | A diagnostic answer to a specific question | Has a symptom rather than a curiosity |
The clearest split is between Viome and Zoe. Viome infers what you should eat from microbial activity. Zoe measures how your body responded to standardized food challenges — glucose over a 14-day sensor and a blood-fat response to a set test meal — and anchors its scoring to that measured response. Neither approach has demonstrated better long-term clinical outcomes than general dietary advice, but they are personalizing from different evidence. If measured physiology is more persuasive to you than a microbial model, that is the more relevant difference than price. Our Viome vs Zoe comparison sets the two side by side against the same rubric.
Clinical testing is not a like-for-like alternative, because it answers a different question. If your motivation is a symptom, the clinical route is cheaper, frequently insurance-covered, and diagnostic. If your motivation is curiosity and a structured food framework, clinical testing has nothing to offer you.
Related
- Zoe review
- Viome vs Zoe
- Best gut health test — match the test to your question
- Gut health hub
- hs-CRP — the inflammation marker worth pairing with gut work
Frequently Asked Questions
What is Viome and what does it actually measure?
Viome is a direct-to-consumer gut testing product. You collect a stool sample at home, mail it back, and the company sequences RNA from the microbes in it. RNA sequencing, or metatranscriptomics, reports which organisms are transcribing genes at the moment of collection rather than only which organisms are present. From that signal Viome generates activity scores and a personalized ranking of foods, and it sells supplement formulations derived from the same results. It is a wellness product, not a diagnostic device, and it is not regulated as one.
How much does Viome cost in 2026?
Tests run roughly $149 to $399 depending on the tier, with the entry tier covering the gut sample alone and higher tiers adding blood-based and oral-microbiome components. Supplements are a separate subscription, commonly in the $60 to $200 per month range depending on the formulation. Prices move with promotions and with subscription commitments, so confirm current figures on the company site. The number that matters for budgeting is the multi-year one: the product is built around annual retesting, so a single test price understates the intended cost.
Is RNA sequencing actually better than DNA sequencing for gut testing?
It answers a different question, and it has a specific practical weakness. DNA sequencing identifies which organisms are present, including dead ones that simply passed through, and which genes they carry. RNA sequencing measures expression, so it reports activity. That is the richer signal in principle. In practice RNA degrades within hours, which makes shipping conditions and transit time a real source of variation in a mail-order product. Reference databases for interpreting expression are also smaller than the DNA equivalents. A method that is better in a laboratory is not automatically better in a kit.
How reproducible are Viome results?
Microbiome profiles are unstable on short timescales for reasons that have nothing to do with the lab. Diet, sleep, travel, stress and medication all shift composition, and two samples from the same person days apart can differ noticeably. Layer RNA fragility on top and short-interval retesting becomes hard to interpret. The practical rule is to retest no sooner than three months, hold conditions steady between samples, and avoid testing within one to three months of antibiotics. Comparing a Viome result against another vendor’s result is not meaningful at all, because the methods and reference models differ.
Are the food recommendations evidence-based?
The sequencing is legitimate science. The food-scoring model built on top of it is proprietary, and independent validation of the specific rankings is limited. No published evidence establishes that eating according to Viome scores produces better long-term clinical outcomes than general dietary guidance. Users also encounter results that contradict mainstream nutrition — a food with strong general evidence scoring poorly for them individually. That can reflect a real personal response or an artifact of the model, and the report does not let you tell which. Treat scores as directional.
Does Viome selling supplements create a conflict of interest?
It creates an incentive worth accounting for. The company that interprets your data also sells the products the interpretation recommends, which means the recommendation engine and the revenue model point the same way. That does not make any specific recommendation wrong, and the arrangement is disclosed rather than hidden. It does mean the report is not an independent read of your sample, and a reader should discount it the way they would discount any vendor-generated recommendation for the vendor’s own product. You are not obliged to buy the supplements to use the test.
Can Viome diagnose SIBO, IBS, or IBD?
No, and each has a different correct test. Small intestinal bacterial overgrowth is diagnosed with a timed lactulose or glucose breath test, because a stool sample reflects the colon and cannot see the small intestine at all. Inflammatory bowel disease versus irritable bowel syndrome is separated by fecal calprotectin, then imaging and endoscopy. Neither is included in a consumer microbiome panel. If you have persistent symptoms, especially with bleeding, weight loss, fever, anemia, or diarrhea that wakes you at night, the workup should start with a clinician.
Who should buy something else instead?
Anyone with a symptom rather than a curiosity, because a symptom has a matched clinical test that is usually cheaper and frequently covered by insurance. Anyone who has never run a comprehensive blood panel, because fasting insulin, HbA1c, ApoB, and hs-CRP name specific treatable problems for less money. Anyone who wants personalization anchored to measured physiological responses rather than to a microbial model, which is closer to what Zoe is built to do. And anyone who will only ever test once, because a single reading with no comparison point is the weakest version of this product.